A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
Status:
Not yet recruiting
Trial end date:
2023-01-02
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics,
safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients
from birth to less than 18 years old hospitalized with COVID-19 and who are receiving
systemic corticosteroids and require supplemental oxygen or mechanical ventilation.